News

The first domestic teriflunomide tablets were sold on the market, and the drug security for rare diseases ushered in new hope

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2022-08-10
  • Views:0

(Summary description)Today, the first domestic teriflunomide tablets developed by Shengshi Tyco are on sale. The first batch of patients will benefit Beijing, Shanghai, Guangzhou, Chengdu, Suzhou and other core cities. The follow-up will soon cover the national market, bringing new choices and drug supply guarantees for domestic patients with multiple sclerosis.

The first domestic teriflunomide tablets were sold on the market, and the drug security for rare diseases ushered in new hope

(Summary description)Today, the first domestic teriflunomide tablets developed by Shengshi Tyco are on sale. The first batch of patients will benefit Beijing, Shanghai, Guangzhou, Chengdu, Suzhou and other core cities. The follow-up will soon cover the national market, bringing new choices and drug supply guarantees for domestic patients with multiple sclerosis.

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2022-08-10
  • Views:0

Today, the first domestic teriflunomide tablets developed by Shengshi Tyco are on sale. The first batch of patients will benefit Beijing, Shanghai, Guangzhou, Chengdu, Suzhou and other core cities. The follow-up will soon cover the national market, bringing new choices and drug supply guarantees for domestic patients with multiple sclerosis.


Multiple sclerosis (MS) is a lifelong, chronic and progressive disease. More than 2.3 million people worldwide suffer from multiple sclerosis, and nearly 50000 patients in China. In May 2018, multiple sclerosis was included in the first list of rare diseases in China. Its etiology originates from the pathological changes of the autoimmune system, causing the damage and peeling of the nerve myelin sheath, resulting in the damage of the spinal cord, brain and optic nerve functions. The patient's nervous system disability gradually worsens, and the patient loses self-care ability, blindness and even life. Early diagnosis and treatment are required.

Teriflunomide is an immune modulator with anti-inflammatory effect. It has definite efficacy and good safety when taken for a long time. It is the first-line drug recommended by domestic and foreign guidelines for the treatment of multiple sclerosis. The telifloxamine tablets developed by Shengshi Tyco passed the consistency evaluation with the original drugs. The marketing broke the current situation of excessive dependence on imported drugs for the treatment of multiple sclerosis. It will significantly improve the drug availability of domestic patients, ensure the continuity of drug supply, and not be affected by various overseas factors.

Dr. Yu Qiang, founder and CEO of Shengshi Tyco, said: "In fact, rare diseases are not rare. But there is no medicine to cure, which is the unspeakable pain of patients with rare diseases. The earlier the diagnosis and treatment of multiple sclerosis are, the better the symptoms can be alleviated and the development of the disease can be delayed. Therefore, today we are glad to see that the terfloxacin tablets produced by Shengshi Tyco are sold on the market, benefiting domestic patients and making every small group no longer give up. In the future, the company will focus on the unmet needs of China and the world Guided by clinical needs, we will develop innovative drugs with high accessibility and better efficacy to benefit patients worldwide. "

Founded in Suzhou Industrial Park in 2010, Shengshi Tyco is committed to the R & D and industrialization of small molecule innovative drugs for breakthrough therapies. Relying on the integrated drug R & D technology platform and diversified business vision, the company has built a rich pipeline of innovative drugs, covering many disease fields such as glucose lowering, anticancer and rare diseases. Among them, the original hypoglycemic new drug shenggliptin phosphate has entered the final stage of clinical phase III, which is expected to fill the gap of domestic original DPP-4 inhibitors; Three of the anticancer drugs under research have entered the clinic. The FGFR / VEGFR dual target inhibitor cgt-6321 has been carried out in phase I clinical trials in advanced solid tumors, and this drug is expected to become a potential first in class drug; CXCR4 antagonist cgt-1881 is used for hematopoietic stem cell mobilization, and oral administration is more convenient; Cgt-9475, a new generation ALK / ret inhibitor, is expected to solve several major clinical pain points such as drug resistance and brain metastasis in the treatment of lung cancer. Both of the latter two projects have obtained the clinical approval of the US FDA, which has taken a solid step in the company's innovative drugs going to sea.

The

The world's first SGLT-2/DPP-4 dual target inhibitor with complementary advantages has been approved for clinical use

Recently, Shengshi Taike's Class 1 innovative drug SGLT-2/DPP-4 dual target inhibitor CGT-2201 has been granted implicit permission for clinical trials by the National Drug Administration. CGT-2201, which targets SGLT-2 and DPP-4, two important targets related to glucose metabolism, can be better used for the treatment of diabetes and its derivatives, including diabetes nephropathy and non-alcoholic fatty liver disease. In 2021, the number of diabetes patients in China will reach 141 million, ranking first in the world. Among the numerous patients with diabetes in China, 20-40% may suffer from complications of diabetes nephropathy. Among the existing hypoglycemic drugs, only sodium glucose cotransporter 2 (SGLT-2) inhibitor has significant renal protection effect in clinical verification, but its inherent reproductive and urinary system infection risks limit its use. Based on SGLT-2 inhibitors and combined with the characteristics of dipeptidyl peptidase 4 (DPP-4) inhibitors, we design and develop a drug that can improve blood sugar, reduce side effects of urinary and reproductive system infections, is not limited by renal function, and has kidney benefits. It is expected to fill the market gap and meet the needs of patients. Based on this market background and target characteristics, Shengshi Taike utilizes its own small molecule chimera drug technology platform to develop multi head multifunctional new drug products with synergistic mechanisms, with CGT-2201 being one of its representative works. It fuses the respective mechanism characteristics of SGLT-2 and DPP-4. On the basis of inhibiting the activity of SGLT-2 to reduce the reabsorption of glucose in the kidney, it also slows down the inactivation of DPP-4 on GLP-1, playing a dual role mechanism to play a superposition effect; While achieving considerable hypoglycemic effect, it can reduce the side effects of existing SGLT-2 drug urinary system infection; At the same time, without kidney excretion, it can reduce the burden of the kidney and reduce the contraindication of diabetes patients with renal insufficiency. Therefore, this drug will have the advantage of better controlling blood sugar and protecting patient kidney function. Shengshi Tyco was founded in Suzhou Industrial Park in 2010. Its core team has decades of experience in the whole life cycle of international drugs, and is committed to the R&D and industrialization of high-quality and differentiated small molecule innovative drugs. The company has built a product pipeline covering multiple disease fields such as hypoglycemic, anticancer, and autoimmune diseases with an integrated drug research and development technology platform and a diversified business perspective. In the field of hypoglycemic drugs, Shenggliptin, the core product independently developed by the company, has submitted an NDA (product launch application) to the National Drug Administration and has been accepted. The results of the Phase 3 clinical trial showed that low doses can reach the predetermined trial endpoint, while the high-dose group can also demonstrate the safety of the drug well. The therapeutic effect of "half the dose" is twice as effective, making it expected to become the best hypoglycemic drug in the class. At the same time, the company has also carried out a comprehensive layout around oral drugs and derivative diseases of various targets related to diabetes. CGT-2201, which was approved for clinical use this time, is one of its pipeline matrix members.
2023-04-20

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO